Aquestive therapeutics, inc. (AQST)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-68,050

-66,246

-67,554

-64,180

-80,201

-61,376

0

0

0

Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization

0

-

-

-

0

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

0

0

0

Change in fair value of warrant

-

-

-

-

-

5,278

0

0

0

Share-based compensation

7,411

7,071

6,598

5,965

31,460

29,940

0

0

0

Asset retirement obligation accretion

-

-

-

-

-

-

0

0

0

Amortization of intangible

-

-

-

-

-

-

0

0

0

Amortization of debt issuance costs and discounts

2,124

1,929

1,737

1,554

1,627

1,696

0

0

0

Non-cash interest expense

-168

359

0

0

0

-

-

-

-

All other non-cash expenses

0

-

-

-

0

-

-

-

-

Interest received other than in cash for example by issuing additional debt securities.

-

-

-

-

-

-

-

0

0

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable and amount of direct write-downs of accounts receivable charged against the allowance.

-

-

-

-

-

-

0

0

0

Other, net

-

-

-

-

-

-

-

0

0

Changes in operating assets and liabilities:
Trade receivables and other receivables

0

-

-

0

0

-

-

0

0

Inventories, net

-2,050

-2,582

-359

299

1,288

1,427

0

0

0

Prepaid expenses and other current assets

0

-

-

-

0

-

-

-

-

Prepaid expenses and other current assets

-

-

-

-

-

-

-

0

0

Accounts payable and accrued expenses

0

-

0

0

0

-

0

0

0

Deferred revenue

1,767

1,601

-651

-1,200

-897

-626

0

0

0

Net cash used for operating activities

-56,167

-60,210

-52,447

-49,133

-31,456

-12,991

0

0

0

Cash flows from investing activities:
Capital expenditures

418

663

1,067

1,424

1,941

1,824

0

0

0

Net cash used for investing activities

-418

-663

-1,067

-1,424

-1,941

-1,824

0

0

0

Cash flows from financing activities:
Payments for deferred offering costs

-

-

-

-

-

-

0

0

0

Payments for taxes on share-based compensation

255

2,827

2,847

3,068

8,636

6,027

0

0

0

Net cash used for financing activities

52,172

49,600

10,446

62,084

56,843

58,035

0

0

0

Net decrease in cash and cash equivalents

-4,413

-11,273

-43,068

11,527

23,446

43,220

0

0

0

Supplemental disclosures of cash flow information:
Cash payments for interest

8,519

7,340

6,691

5,656

5,573

6,049

0

0

0

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

0

-

-

-

0

-

-

-

-

Increase (decrease) in future cash outflow to pay for purchases of fixed assets that have occurred.

-

-

-

-

-

-

-

-

0

Increase (decrease) in future cash outflow to pay for deferred offering costs that have occurred.

-311

0

89

-2,282

-277

-588

0

0

0

Withholding tax payments accrued on share based compensation.

3

0

814

774

2,511

2,515

0

0

0